<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • There are no suggestions because the search field is empty.

Next-Generation Biologics in Oncology

Date: March 11, 2026 - 10:30 - 14:00 GMT

Location: The Studio, The Westworks, 195 Wood Lane, White City, London, W12 7FQ

The biologics revolution in oncology is happening now, and the companies shaping this future are here to share their breakthroughs with you. This isn't another theoretical conference – you'll hear directly from innovators developing tomorrow's cancer treatments today.

Gain unprecedented access to proprietary insights from Crown Bioscience and three cutting-edge biotechs actively advancing novel therapeutic platforms. Learn the critical translation strategies that separate successful programs from failed ones, understand the latest innovations in targeted drug delivery, and discover how advanced modeling is revolutionizing preclinical development.

Whether you're seeking competitive intelligence, partnership opportunities, or simply want to stay ahead of the rapidly evolving oncology landscape, this event offers direct dialogue with innovators who are defining the next generation of cancer therapeutics. 

Spaces are limited. Light lunch will be served. Reserve your seat now and be part of the conversation!

What You'll Discover:

  • Advanced Translation Strategies - Learn how innovative in vitro and in vivo modeling is accelerating the path from bench to bedside

  • Next-Generation Platforms - Explore breakthrough approaches in peptide drug conjugates and targeted delivery systems

  • Real-World Applications - Gain practical insights from companies actively developing the next wave of cancer biologics

Agenda:

  • Registration at 10:30am
  • Talks start at 11:00am
  • 15 minutes coffee break at 12pm-12:15pm
  • Networking and light lunch at 1:15pm
  • Closing at 2:00pm

Spaces are limited. Light lunch will be served. Reserve your seat now and be part of the conversation! 


Our expert speakers:

Rajendra Kumari, PhD

Executive Director, Integrated Solutions

Victoria Juskaite, PhD

Principal Scientist, Avacta Therapeutics

Talk Title: Integrating Advanced In Vitro and In Vivo Models to Support Translation of FAP-Enabled pre|CISION®-Peptide Drug Conjugates

Rahul Khanolkar

Director of Pre-clinical development, Accession Therapeutics

Valentina Galli

Associate Research Director Translational Biology, NanoSyrinx

Share This

Reserve your seat today!

Your privacy is important to us.
We'll never share your information.